The Specialty Pharma Market Outlook - Key players, new company growth models and emerging opportunities

While the specialty pharma sector has traditionally capitalized on opportunities from Big Pharma, competitive pressures and the maturing market are forcing them to develop new specialization strategies. These pressures, such as commoditization of drug delivery technologies and competition from foreign bulk generics manufacturers, are driving new company growth models and a focus on targeted portfolios, stronger late-stage drug development capabilities, M&A and in-licensing activity.

The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities evaluates current specialty pharma models, financial performance, core strategies and future outlook of specialty pharma companies. This report also examines key specialty markets, providing valuable insights into market dynamics while profiling trends influencing market opportunities in therapeutic indications.

This report will provide you with:

An overview of the specialty pharmaceutical sector, including segmentation by company type and analysis of deal-flow, licensing and M&A activity.

Detailed product portfolios and SWOT analysis of companies operating in the sector, including Allergan, Shire, Biovail, Watson, KV and Elan, enabling you to assess the attractiveness of specialty pharmas as acquisition licensing targets.

The financial performance of companies operating in this sector, enabling you to identify key players and benchmark your financial position against specialty pharma industry leaders.

In-depth analysis of the major therapy areas including: cardiovascular, CNS, ophthalmology, dermatology, women’s health and urology and the companies active in these therapeutic areas, ensuring you are able to identify the key players in your market and understand future therapeutic opportunities and threats.

Recommended growth models highlighting strategies for future success.

Discover how leaders in the specialty pharma market are achieving high growth, benchmark your strategies against those of the industry’s leaders and identify profitable partnering opportunities with the help of this new report.

Published: October 2006 Format PDF
Table of Contents
Full Table of Contents (PDF)
Price: $2,875.00 / GBP1,897.50